Navigation Links
Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

SAN DIEGO, May 15, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase), an investigational new biologic, in combination with gemcitabine for treatment of patients with stage IV metastatic pancreatic cancer will be presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

In this Phase 1b study, 28 stage IV pancreatic ductal adenocarcinoma patients were treated with PEGPH20 in combination with gemcitabine. The overall response rate (CR+PR) was 42 percent* (n=24) as assessed by independent review at therapeutic dose levels of PEGPH20 (1.6 and 3.0 µg/kg). Treatment was generally well tolerated and the adverse event profile was consistent with those seen in previous studies of PEGPH20 as a single agent and as previously reported for gemcitabine alone. There was no evidence of new observed toxicity. Detailed clinical data, including CA 19-9 and pharmacodynamic results will be presented at the meeting.

Emerging data show that most pancreatic cancers surround themselves with a protective hyaluronan-rich matrix, which makes the disease difficult to treat and is itself an indicator of poor prognosis. PEGPH20 depletes this matrix component from the tumor and rapidly changes the tumor microenvironment and metabolism, which may render it more vulnerable to therapy as well as inhibit tumor growth.

"Data from this single arm Phase 1b study clearly reinforce the hypothesis of treating pancreatic cancer with PEGPH20 in conjunction with chemotherapeutic agents," said Joy Zhu , M.D., Ph.D., Vice President, Oncology Clinical Development,
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
3. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
4. Halozyme to Host Second Quarter Financial Results Conference Call
5. Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
8. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... California (PRWEB) July 31, 2014 CollabRx, ... that inform therapeutic decision-making in oncology, today announced that ... 14, 2014 to discuss the Company's financial results for ... an update about the business in the current fiscal ... call beginning on Thursday, August 14, 2014, at 5 ...
(Date:7/31/2014)... , July 31, 2014  Smith & Nephew ... medical technology business, today announced its entry into ... HAT-TRICK™ Lesser Toe Repair System. Comprised of three ... for metatarsophalangeal (MTP) ligament repair and reconstruction, a ... for proximal Inter-phalanges (PIP) fusion, also known as ...
(Date:7/31/2014)... Calif. (PRWEB) July 31, 2014 Held ... diagnosed patients with an overview of the disease and ... of drug side effects, as well as updates on ... grateful to Dr. Sandy Srinivas for organizing this educational ... of kidney cancer. “Sandy and her colleagues have put ...
(Date:7/31/2014)... The global market for molecular diagnostics is ... to a new study by Grand View Research, Inc. ... subsequent introduction of advanced cancer diagnostic technologies are expected ... next six years. Moreover, the growing global base of ... with disease triggering lifestyle habits such as smoking and ...
Breaking Biology Technology:CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 3Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5
... ... Walker formed MEDS World, LLC, launching innovative odor elimination, exterior plastic trim and headlight ... over fifty years of management experiences, in a myriad of industries, to introduce these ... http://www.meds-world.com , ...
... Fred Hutchinson Cancer Research Center board of trustees today announced ... retire in June 2010. Hartwell, a recipient of the 2001 ... director of the Hutchinson Center since 1997. , ... director of the Center for 12 years. It,s time for ...
... Ga., June 26 Immucor, Inc., (Nasdaq/NM: BLUD), a global ... industry, announced that yesterday the Food and Drug Administration ("FDA"), ... inspection, issued a notice of intent to revoke the Company,s ... and Anti-E (Monoclonal) Blood Grouping Reagent product. The FDA ...
Cached Biology Technology:MEDS World, LLC Provides Multiple Environments with Designed Solutions - Wherever People Congregate, MEDS Odor Elimination Solutions Offer Eco-Friendly, Odor-Free Air 2MEDS World, LLC Provides Multiple Environments with Designed Solutions - Wherever People Congregate, MEDS Odor Elimination Solutions Offer Eco-Friendly, Odor-Free Air 3Nobel Laureate Lee Hartwell to Retire as President and Director of Fred Hutchinson Cancer Research Center in 2010 2Immucor Responds To FDA Notice 2
(Date:7/31/2014)... study (HPV-023; NCT00518336) shows the sustained efficacy, ... virus (HPV) vaccine Cervarix. Women vaccinated with ... more than nine years, and vaccine efficacy ... is the longest follow-up report for a ... for the full paper. , HPV ...
(Date:7/31/2014)... in German . ... similar to a sponge that soaks up liquids. Hence, ... or greenhouse gases. However, loading of many MOFs is ... (KIT) now report in Nature Communications that ... surface. This can be prevented by water-free synthesis and ...
(Date:7/31/2014)... the photovoltaic effect in 1839, humankind has sought to ... its own purposes. In a new research report published ... FASEB Journal , scientists may have uncovered a ... focusing on a naturally occurring combination of lipids that ... over time and across speciessuggests that this specific natural ...
Breaking Biology News(10 mins):Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3Free pores for molecule transport 2Scientists shine bright new light on how living things capture energy from the sun 2
... of vitamin C were associated with higher levels of high ... issues or death for heart failure patients, in research presented ... to those with high vitamin C intake from food, heart ... intake were 2.4 times more likely to have higher levels ...
... Clinical benefit from use of a novel histone deacetylase ... days after a patient receives treatment. The drug, entinostat, ... a randomized, placebo-controlled study in metastatic breast cancer ... can be predicted shortly after administration. The findings, ...
... Lysmata amboinensis usually live in monogamous pairs, but ... BioMed Central,s open access journal Frontiers in Zoology ... viciously attack and kill each other until only a single ... hermaphrodites. This means that they start out as males but, ...
Cached Biology News:Low vitamin C levels may raise heart failure patients' risk 2Benefit of novel drug in breast cancer seen in blood within weeks 2Violent passions -- jealous cleaner shrimp murder their rivals 2
... Streptavidin-AP Systems provide rapid, precise localization ... in frozen or paraffin-embedded tissue, cytospins ... also facilitate double or triple labeleing ... simultaneously with primary antibodies of different ...
... Streptavidin-HRP Systems provide rapid, precise localization ... in frozen or paraffin-embedded tissue, cytospins ... also facilitate double or triple labeleing ... simultaneously with primary antibodies of different ...
... be used with all 96-well ... stacking of covered plates ... with automated systems ... are available for use with ...
... Chromatography requirements, IonQuest will provide ... The newly developed conductivity detector has ... ultra-low drift . The use ... creates even higher sensitivities for anions, ...
Biology Products: